Andrew D Dick

List of Publications by Year in Descending Order

278 papers	9,519 citations	54 h-index	84 g-index
295 ext. papers	11,364 ext. citations	6.7 avg, IF	6.18 L-index

#	Paper	IF	Citations
278	Applications of Three-dimensional Printing in Ophthalmology.. *Survey of Ophthalmology*, **2022**,	6.1	1
277	Recent developments of neuroprotective agents for degenerative retinal disorders.. *Neural Regeneration Research*, **2022**, 17, 1919-1928	4.5	2
276	Ocular Toxoplasmosis Associated Dark Without Pressure.. *Ocular Immunology and Inflammation*, **2022**, 1-3	2.8	
275	Long-term efficacy and tolerability of TNF inhibitors in the treatment of non-infectious ocular inflammation: an 8-year prospective surveillance study. *British Journal of Ophthalmology*, **2021**, 105, 1256-1262	5.5	15
274	The Cellular Composition of the Uveal Immune Environment. *Frontiers in Medicine*, **2021**, 8, 721953	4.9	0
273	Interleukin-33 regulates metabolic reprogramming of the retinal pigment epithelium in response to immune stressors. *JCI Insight*, **2021**, 6,	9.9	2
272	Inflammation in Viral Vector-Mediated Ocular Gene Therapy: A Review and Report From a Workshop Hosted by the Foundation Fighting Blindness, 9/2020. *Translational Vision Science and Technology*, **2021**, 10, 3	3.3	2
271	Emerging therapies and their delivery for treating age-related macular degeneration. *British Journal of Pharmacology*, **2021**,	8.6	6
270	Achieving Quiescence with Fluocinolone Implants. *Case Reports in Ophthalmology*, **2021**, 12, 356-362	0.7	1
269	Epidemiology of Scleritis in the United Kingdom From 1997 to 2018: Population-Based Analysis of 11 Million Patients and Association Between Scleritis and Infectious and Immune-Mediated Inflammatory Disease. *Arthritis and Rheumatology*, **2021**, 73, 1267-1276	9.5	3
268	Quantitative Assessment of Experimental Ocular Inflammatory Disease. *Frontiers in Immunology*, **2021**, 12, 630022	8.4	1
267	Adalimumab in the treatment of pediatric patients with chronic noninfectious anterior uveitis. *Expert Review of Ophthalmology*, **2021**, 16, 231-241	1.5	0
266	Juvenile Idiopathic Arthritis Associated Uveitis. *Children*, **2021**, 8,	2.8	1
265	Long-Term Safety and Efficacy of Adalimumab in Patients with Noninfectious Intermediate Uveitis, Posterior Uveitis, or Panuveitis. *Ophthalmology*, **2021**, 128, 899-909	7.3	6
264	Imaging-Based Uveitis Surveillance in Juvenile Idiopathic Arthritis: Feasibility, Acceptability, and Diagnostic Performance. *Arthritis and Rheumatology*, **2021**, 73, 330-335	9.5	4
263	Patient-reported wellbeing and clinical disease measures over time captured by multivariate trajectories of disease activity in individuals with juvenile idiopathic arthritis in the UK: a multicentre prospective longitudinal study. *Lancet Rheumatology, The*, **2021**, 3, e111-e121	14.2	5
262	Treatment of psoriatic arthritis with biologic and targeted synthetic DMARDs: British Society for Rheumatology guideline scope. *Rheumatology*, **2021**, 60, 1588-1592	3.9	0

261	Intermediate uveitis associated with MS: Diagnosis, clinical features, pathogenic mechanisms, and recommendations for management. *Neurology: Neuroimmunology and NeuroInflammation*, **2021**, 8,	9.1	2
260	Cellular senescence in the aging retina and developments of senotherapies for age-related macular degeneration. *Journal of Neuroinflammation*, **2021**, 18, 32	10.1	20
259	Engineering adeno-associated viral vectors to evade innate immune and inflammatory responses. *Science Translational Medicine*, **2021**, 13,	17.5	38
258	Unravelling the therapeutic potential of IL-33 for atrophic AMD. *Eye*, **2021**,	4.4	1
257	Peptide-based immunotherapy against oxidized elastin ameliorates pathology in mouse model of smoke-induced ocular injury. *Experimental Eye Research*, **2021**, 212, 108755	3.7	0
256	Corneal Transplant Follow-up Study II: a randomised trial to determine whether HLA class II matching reduces the risk of allograft rejection in penetrating keratoplasty. *British Journal of Ophthalmology*, **2020**,	5.5	2
255	Ambient Air Pollution Associations with Retinal Morphology in the UK Biobank **2020**, 61, 32		15
254	Personal protective equipment (PPE) for vitreoretinal surgery during COVID-19. *Eye*, **2020**, 34, 1196-1198	4.4	14
253	Treatment of diabetic retinopathy through neuropeptide Y-mediated enhancement of neurovascular microenvironment. *Journal of Cellular and Molecular Medicine*, **2020**, 24, 3958-3970	5.6	8
252	Tocilizumab in patients with anti-TNF refractory juvenile idiopathic arthritis-associated uveitis (APTITUDE): a multicentre, single-arm, phase 2 trial. *Lancet Rheumatology, The*, **2020**, 2, e135-e141	14.2	35
251	Intravenous indocyanine green dye is insufficient for robust immune cell labelling in the human retina. *PLoS ONE*, **2020**, 15, e0226311	3.7	1
250	Gene Therapy for Glaucoma by Ciliary Body Aquaporin 1 Disruption Using CRISPR-Cas9. *Molecular Therapy*, **2020**, 28, 820-829	11.7	27
249	Activation of C-reactive protein proinflammatory phenotype in the blood retinal barrier : implications for age-related macular degeneration. *Aging*, **2020**, 12, 13905-13923	5.6	5
248	Comparison of Associations with Different Macular Inner Retinal Thickness Parameters in a Large Cohort: The UK Biobank. *Ophthalmology*, **2020**, 127, 62-71	7.3	20
247	Features of ectopic lymphoid-like structures in human uveitis. *Experimental Eye Research*, **2020**, 191, 107901	3.7	9
246	Treatment with interleukin-33 is non-toxic and protects retinal pigment epithelium in an ageing model of outer retinal degeneration. *Journal of Cellular and Molecular Medicine*, **2020**, 24, 13546-13550	5.6	3
245	Discontinuing adalimumab in patients with controlled juvenile idiopathic arthritis-associated uveitis (ADJUST-Adalimumab in Juvenile Idiopathic Arthritis-associated Uveitis Stopping Trial): study protocol for a randomised controlled trial. *Trials*, **2020**, 21, 887	2.8	6
244	Areas of agreement in the management of childhood non-infectious chronic anterior uveitis in the UK. *British Journal of Ophthalmology*, **2020**, 104, 11-16	5.5	8

243	Management of paediatric ocular inflammatory disease in the UK: national survey of practice. *Eye*, **2020**, 34, 591-592	4.4	2
242	Intravenous indocyanine green dye is insufficient for robust immune cell labelling in the human retina **2020**, 15, e0226311		
241	Intravenous indocyanine green dye is insufficient for robust immune cell labelling in the human retina **2020**, 15, e0226311		
240	Intravenous indocyanine green dye is insufficient for robust immune cell labelling in the human retina **2020**, 15, e0226311		
239	Intravenous indocyanine green dye is insufficient for robust immune cell labelling in the human retina **2020**, 15, e0226311		
238	Associations with Corneal Hysteresis in a Population Cohort: Results from 96 010 UK Biobank Participants. *Ophthalmology*, **2019**, 126, 1500-1510	7.3	14
237	A review and update on the ophthalmic implications of Susac syndrome. *Survey of Ophthalmology*, **2019**, 64, 477-485	6.1	16
236	Adalimumab in Juvenile Idiopathic Arthritis-Associated Uveitis: 5-Year Follow-up of the Bristol Participants of the SYCAMORE Trial. *American Journal of Ophthalmology*, **2019**, 207, 170-174	4.9	23
235	Restoring retinal neurovascular health via substance P. *Experimental Cell Research*, **2019**, 380, 115-123	4.2	7
234	Single Eye mRNA-Seq Reveals Normalisation of the Retinal Microglial Transcriptome Following Acute Inflammation. *Frontiers in Immunology*, **2019**, 10, 3033	8.4	9
233	Clinical spectrum of vitreoretinal lymphoma and its association with MyD88 L265P mutation. *Acta Ophthalmologica*, **2019**, 97, e138-e139	3.7	6
232	Adalimumab in Active and Inactive, Non-Infectious Uveitis: Global Results from the VISUAL I and VISUAL II Trials. *Ocular Immunology and Inflammation*, **2019**, 27, 40-50	2.8	12
231	A systems biology approach towards understanding and treating non-neovascular age-related macular degeneration. *Nature Communications*, **2019**, 10, 3347	17.4	104
230	Modelling Macular Edema: The Effect of IL-6 and IL-6R Blockade on Human Blood-Retinal Barrier Integrity In Vitro. *Translational Vision Science and Technology*, **2019**, 8, 32	3.3	14
229	Adalimumab in combination with methotrexate for refractory uveitis associated with juvenile idiopathic arthritis: a RCT. *Health Technology Assessment*, **2019**, 23, 1-140	4.4	10
228	MÜller Cells Stabilize Microvasculature through Hypoxic Preconditioning. *Cellular Physiology and Biochemistry*, **2019**, 52, 668-680	3.9	6
227	Reply. *Ophthalmology*, **2019**, 126, e24-e25	7.3	
226	The Relationship Between Ambient Atmospheric Fine Particulate Matter (PM2.5) and Glaucoma in a Large Community Cohort **2019**, 60, 4915-4923		27

225	Reduced Macular Vessel Density and Capillary Perfusion in Glaucoma Detected Using OCT Angiography. *Current Eye Research*, **2019**, 44, 533-540	2.9	21
224	Cost-Effectiveness Analysis of Adalimumab for the Treatment of Uveitis Associated with Juvenile Idiopathic Arthritis. *Ophthalmology*, **2019**, 126, 415-424	7.3	14
223	Corneal transplant follow-up study II (CTFS II): a prospective clinical trial to determine the influence of HLA class II matching on corneal transplant rejection: baseline donor and recipient characteristics. *British Journal of Ophthalmology*, **2019**, 103, 132-136	5.5	3
222	Autoimmunity, Autoinflammation, and Infection in Uveitis. *American Journal of Ophthalmology*, **2018**, 189, 77-85	4.9	62
221	Efficacy and safety of intravitreal anti-tumour necrosis factor drugs in adults with non-infectious uveitis - a systematic review. *Acta Ophthalmologica*, **2018**, 96, e665-e675	3.7	13
220	Combined immunosuppression and radiotherapy in thyroid eye disease (CIRTED): a multicentre, 2 ⍰2 factorial, double-blind, randomised controlled trial. *Lancet Diabetes and Endocrinology,the*, **2018**, 6, 299-309	18.1	42
219	Safety and Efficacy of Adalimumab in Patients with Noninfectious Uveitis in an Ongoing Open-Label Study: VISUAL III. *Ophthalmology*, **2018**, 125, 1075-1087	7.3	81
218	Guidance on Noncorticosteroid Systemic Immunomodulatory Therapy in Noninfectious Uveitis: Fundamentals Of Care for UveitiS (FOCUS) Initiative. *Ophthalmology*, **2018**, 125, 757-773	7.3	97
217	Re-programming immunosurveillance in persistent non-infectious ocular inflammation. *Progress in Retinal and Eye Research*, **2018**, 65, 93-106	20.5	5
216	Bevacizumab for treatment of choroidal neovascularization secondary to candida chorioretinitis. *International Ophthalmology*, **2018**, 38, 781-785	2.2	2
215	Serum Vascular Endothelial Growth Factor Levels in the IVAN Trial; Relationships with Drug, Dosing, and Systemic Serious Adverse Events. *Ophthalmology Retina*, **2018**, 2, 118-127	3.8	16
214	Blau Syndrome-Associated Uveitis: Preliminary Results From an International Prospective Interventional Case Series. *American Journal of Ophthalmology*, **2018**, 187, 158-166	4.9	40
213	A Perspective of AMD Through the Eyes of Immunology **2018**, 59, AMD83-AMD92		31
212	C-Reactive Protein as a Therapeutic Target in Age-Related Macular Degeneration. *Frontiers in Immunology*, **2018**, 9, 808	8.4	25
211	A phase II trial protocol of Tocilizumab in anti-TNF refractory patients with JIA-associated uveitis (the APTITUDE trial). *BMC Rheumatology*, **2018**, 2, 4	2.9	18
210	Outcomes of non-infectious Paediatric uveitis in the era of biologic therapy. *Pediatric Rheumatology* , **2018**, 16, 51	3.5	39
209	Reply. *Ophthalmology*, **2018**, 125, e54	7.3	
208	The Bromodomain and Extra-Terminal Protein Inhibitor OTX015 Suppresses T Helper Cell Proliferation and Differentiation. *Current Molecular Medicine*, **2018**, 18, 594-601	2.5	1

207	Interobserver Agreement Among Uveitis Experts on Uveitic Diagnoses: The Standardization of Uveitis Nomenclature Experience. *American Journal of Ophthalmology*, **2018**, 186, 19-24	4.9	45
206	Trial protocol: a multicentre randomised trial of first-line treatment pathways for newly diagnosed immune thrombocytopenia: standard steroid treatment versus combined steroid and mycophenolate. The FLIGHT trial. *BMJ Open*, **2018**, 8, e024427	3	16
205	The Eyes Have it: A Rheumatologist© View of Uveitis. *Arthritis and Rheumatology*, **2018**, 70, 1533-1543	9.5	13
204	Hypoxia inducible factors are dispensable for myeloid cell migration into the inflamed mouse eye. *Scientific Reports*, **2017**, 7, 40830	4.9	7
203	Inflammatory eye disease: Pre-treatment assessment of patients prior to commencing immunosuppressive and biologic therapy: Recommendations from an expert committee. *Autoimmunity Reviews*, **2017**, 16, 213-222	13.6	18
202	New insights into the genetic component of non-infectious uveitis through an Immunochip strategy. *Journal of Medical Genetics*, **2017**, 54, 38-46	5.8	14
201	Cataract surgery in uveitis: a multicentre database study. *British Journal of Ophthalmology*, **2017**, 101, 1132-1137	5.5	28
200	Effect of Adalimumab on Visual Functioning in Patients With Noninfectious Intermediate Uveitis, Posterior Uveitis, and Panuveitis in the VISUAL-1 and VISUAL-2 Trials. *JAMA Ophthalmology*, **2017**, 135, 511-518	3.9	42
199	Adalimumab plus Methotrexate for Uveitis in Juvenile Idiopathic Arthritis. *New England Journal of Medicine*, **2017**, 376, 1637-1646	59.2	218
198	Application of OCT-angiography to characterise the evolution of chorioretinal lesions in acute posterior multifocal placoid pigment epitheliopathy. *Eye*, **2017**, 31, 1399-1408	4.4	42
197	Cross sectional, qualitative thematic analysis of patient perspectives of disease impact in juvenile idiopathic arthritis-associated uveitis. *Pediatric Rheumatology*, **2017**, 15, 58	3.5	15
196	Augmenting Endogenous Levels of Retinal Annexin A1 Suppresses Uveitis in Mice. *Translational Vision Science and Technology*, **2017**, 6, 10	3.3	3
195	Adalimumab for Uveitis in Juvenile Idiopathic Arthritis. *New England Journal of Medicine*, **2017**, 377, 789-790	59.2	12
194	Interleukin-33 regulates tissue remodelling and inhibits angiogenesis in the eye. *Journal of Pathology*, **2017**, 241, 45-56	9.4	38
193	Alemtuzumab-induced remission of multiple sclerosis-associated uveitis. *International Ophthalmology*, **2017**, 37, 1229-1233	2.2	5
192	Soluble CD200 Correlates With Interleukin-6 Levels in Sera of COPD Patients: Potential Implication of the CD200/CD200R Axis in the Disease Course. *Lung*, **2017**, 195, 59-68	2.9	7
191	Doyne lecture 2016: intraocular health and the many faces of inflammation. *Eye*, **2017**, 31, 87-96	4.4	27
190	Anatomy of the eye and orbit **2016**, 1-102.e2		8

189	Adalimumab for prevention of uveitic flare in patients with inactive non-infectious uveitis controlled by corticosteroids (VISUAL II): a multicentre, double-masked, randomised, placebo-controlled phase 3 trial. *Lancet, The*, **2016**, 388, 1183-92	40	249
188	An anti-TNF-□antibody mimetic to treat ocular inflammation. *Scientific Reports*, **2016**, 6, 36905	4.9	17
187	Pleiotropic action of CpG-ODN on endothelium and macrophages attenuates angiogenesis through distinct pathways. *Scientific Reports*, **2016**, 6, 31873	4.9	11
186	Risk of Ocular Complications in Patients with Noninfectious Intermediate Uveitis, Posterior Uveitis, or Panuveitis. *Ophthalmology*, **2016**, 123, 655-62	7.3	96
185	Phase IIb clinical trial of ranibizumab for the treatment of uveitic and idiopathic choroidal neovascular membranes. *British Journal of Ophthalmology*, **2016**, 100, 1221-6	5.5	6
184	Multimodal analysis of ocular inflammation using the endotoxin-induced uveitis mouse model. *DMM Disease Models and Mechanisms*, **2016**, 9, 473-81	4.1	31
183	Managing juvenile idiopathic arthritis-associated uveitis. *Survey of Ophthalmology*, **2016**, 61, 197-210	6.1	27
182	The First European Evidence-based Consensus on Extra-intestinal Manifestations in Inflammatory Bowel Disease. *Journal of Crohn's and Colitis*, **2016**, 10, 239-54	1.5	354
181	Evaluation of Objective Vitritis Grading Method Using Optical Coherence Tomography: Influence of Phakic Status and Previous Vitrectomy. *American Journal of Ophthalmology*, **2016**, 161, 172-80.e1-4	4.9	22
180	Genome-Wide Analysis in Swine Associates Corneal Graft Rejection with Donor-Recipient Mismatches in Three Novel Histocompatibility Regions and One Locus Homologous to the Mouse H-3 Locus. *PLoS ONE*, **2016**, 11, e0152155	3.7	8
179	Optical Coherence Tomography Angiography Findings in Dengue-Related Maculopathy: A Case Report. *Ophthalmic Surgery Lasers and Imaging Retina*, **2016**, 47, 1057-1060	1.4	9
178	Immunology of Uveitis **2016**, 39-81		
177	Complement factor H binding of monomeric C-reactive protein downregulates proinflammatory activity and is impaired with at risk polymorphic CFH variants. *Scientific Reports*, **2016**, 6, 22889	4.9	38
176	Impairing autophagy in retinal pigment epithelium leads to inflammasome activation and enhanced macrophage-mediated angiogenesis. *Scientific Reports*, **2016**, 6, 20639	4.9	42
175	Adalimumab in Patients with Active Noninfectious Uveitis. *New England Journal of Medicine*, **2016**, 375, 932-43	59.2	310
174	Direct and indirect resource use, healthcare costs and work force absence in patients with non-infectious intermediate, posterior or panuveitis. *Acta Ophthalmologica*, **2016**, 94, e331-9	3.7	36
173	Clinical outcomes of intravenous immunoglobulin therapy in refractory uveitis. *International Ophthalmology*, **2015**, 35, 281-5	2.2	5
172	IL-4 regulates specific Arg-1(+) macrophage sFlt-1-mediated inhibition of angiogenesis. *American Journal of Pathology*, **2015**, 185, 2324-35	5.8	26

171	Glucocorticoid-resistant Th17 cells are selectively attenuated by cyclosporine A. *Proceedings of the National Academy of Sciences of the United States of America*, **2015**, 112, 4080-5	11.5	49
170	Homeostatic regulation of T cell trafficking by a B cell-derived peptide is impaired in autoimmune and chronic inflammatory disease. *Nature Medicine*, **2015**, 21, 467-475	50.5	64
169	Activated adult microglia influence retinal progenitor cell proliferation and differentiation toward recoverin-expressing neuron-like cells in a co-culture model. *Graefe's Archive for Clinical and Experimental Ophthalmology*, **2015**, 253, 1085-96	3.8	9
168	Role of interleukin 33/ST2 axis in the immune-mediated pathogenesis of age-related macular degeneration. *Lancet, The*, **2015**, 385 Suppl 1, S97	40	5
167	Treatment strategies in primary vitreoretinal lymphoma: a 17-center European collaborative study. *JAMA Ophthalmology*, **2015**, 133, 191-7	3.9	79
166	TNF Regulates SIRT1 Cleavage during Ocular Autoimmune Disease. *American Journal of Pathology*, **2015**, 185, 1324-33	5.8	15
165	Uveitis associated with juvenile idiopathic arthritis. *Nature Reviews Rheumatology*, **2015**, 11, 338-48	8.1	57
164	Optic nerve and retinal features in uveitis associated with juvenile systemic granulomatous disease (Blau syndrome). *Acta Ophthalmologica*, **2015**, 93, 253-7	3.7	18
163	A simple method for in vivo labelling of infiltrating leukocytes in the mouse retina using indocyanine green dye. *DMM Disease Models and Mechanisms*, **2015**, 8, 1479-87	4.1	6
162	Assessing the painful, uninflamed eye in primary care. *BMJ, The*, **2015**, 351, h3216	5.9	
161	Local targeting of the CD200-CD200R axis does not promote corneal graft survival. *Experimental Eye Research*, **2015**, 130, 1-8	3.7	2
160	Long-term outcome in patients with severe alcoholic hepatitis can be reliably determined using an in vitro measure of steroid sensitivity. *Hepatology*, **2015**, 61, 1099	11.2	8
159	A novel pathogenic RBP-3 peptide reveals epitope spreading in persistent experimental autoimmune uveoretinitis. *Immunology*, **2015**, 146, 301-11	7.8	7
158	Heterogeneity of primary outcome measures used in clinical trials of treatments for intermediate, posterior, and panuveitis. *Orphanet Journal of Rare Diseases*, **2015**, 10, 97	4.2	37
157	The role of lipoprotein-associated phospholipase A2 in a murine model of experimental autoimmune uveoretinitis. *PLoS ONE*, **2015**, 10, e0122093	3.7	5
156	Annexin-A1 restricts Th17 cells and attenuates the severity of autoimmune disease. *Journal of Autoimmunity*, **2015**, 58, 1-11	15.5	20
155	Current and future treatments for Behet uveitis: road to remission. *International Ophthalmology*, **2014**, 34, 365-81	2.2	33
154	Multicenter study of intravitreal dexamethasone implant in noninfectious uveitis: indications, outcomes, and reinjection frequency. *American Journal of Ophthalmology*, **2014**, 158, 1136-1145.e5	4.9	90

153	Autoimmune and autoinflammatory mechanisms in uveitis. *Seminars in Immunopathology*, **2014**, 36, 581-94	12	92
152	Objective measurement of vitreous inflammation using optical coherence tomography. *Ophthalmology*, **2014**, 121, 1706-14	7.3	69
151	TLR9 agonist regulates angiogenesis and inhibits corneal neovascularization. *American Journal of Pathology*, **2014**, 184, 1900-10	5.8	18
150	Immune responses in age-related macular degeneration and a possible long-term therapeutic strategy for prevention. *American Journal of Ophthalmology*, **2014**, 158, 5-11.e2	4.9	44
149	Tissue-resident exhausted effector memory CD8+ T cells accumulate in the retina during chronic experimental autoimmune uveoretinitis. *Journal of Immunology*, **2014**, 192, 4541-50	5.3	29
148	The safety and efficacy of noncorticosteroid triple immunosuppressive therapy in the treatment of refractory chronic noninfectious uveitis in childhood. *Journal of Rheumatology*, **2014**, 41, 136-9	4.1	9
147	A randomised controlled trial of the clinical effectiveness, safety and cost-effectiveness of adalimumab in combination with methotrexate for the treatment of juvenile idiopathic arthritis associated uveitis (SYCAMORE Trial). *Trials*, **2014**, 15, 14	2.8	64
146	Systemic therapies for inflammatory eye disease: past, present and future. *BMC Ophthalmology*, **2013**, 13, 18	2.3	19
145	Local therapies for inflammatory eye disease in translation: past, present and future. *BMC Ophthalmology*, **2013**, 13, 39	2.3	37
144	Diagnostic techniques for inflammatory eye disease: past, present and future: a review. *BMC Ophthalmology*, **2013**, 13, 41	2.3	4
143	Functional analysis of retinal microglia and their effects on progenitors. *Methods in Molecular Biology*, **2013**, 935, 271-83	1.4	3
142	Pars plana vitrectomy for vitreoretinal complications of Behçet uveitis. *European Journal of Ophthalmology*, **2013**, 23, 119 - 128	1.9	8
141	Secukinumab in the treatment of noninfectious uveitis: results of three randomized, controlled clinical trials. *Ophthalmology*, **2013**, 120, 777-87	7.3	215
140	SIRT1 activation protects against autoimmune T cell-driven retinal disease in mice via inhibition of IL-2/Stat5 signaling. *Journal of Autoimmunity*, **2013**, 42, 117-29	15.5	36
139	SRPK1 inhibition modulates VEGF splicing to reduce pathological neovascularization in a rat model of retinopathy of prematurity **2013**, 54, 5797-806		31
138	Topical antiangiogenic SRPK1 inhibitors reduce choroidal neovascularization in rodent models of exudative AMD **2013**, 54, 6052-62		50
137	The role of the immune response in age-related macular degeneration. *International Journal of Inflammation*, **2013**, 2013, 348092	6.4	66
136	Behçet disease-associated uveitis successfully treated with golimumab. *Ocular Immunology and Inflammation*, **2013**, 21, 160-2	2.8	50

135	The Standardization of Uveitis Nomenclature (SUN) Project. Development of a clinical evidence base utilizing informatics tools and techniques. *Methods of Information in Medicine*, **2013**, 52, 259-65, S1-6	1.5	84
134	CD200R signaling inhibits pro-angiogenic gene expression by macrophages and suppresses choroidal neovascularization. *Scientific Reports*, **2013**, 3, 3072	4.9	30
133	Assessment and in vivo scoring of murine experimental autoimmune uveoretinitis using optical coherence tomography. *PLoS ONE*, **2013**, 8, e63002	3.7	32
132	Myeloid cells expressing VEGF and arginase-1 following uptake of damaged retinal pigment epithelium suggests potential mechanism that drives the onset of choroidal angiogenesis in mice. *PLoS ONE*, **2013**, 8, e72935	3.7	66
131	Tumor necrosis factor polymorphisms associated with tumor necrosis factor production influence the risk of idiopathic intermediate uveitis. *Molecular Vision*, **2013**, 19, 184-95	2.3	14
130	Interplay between innate and adaptive immunity in the development of non-infectious uveitis. *Progress in Retinal and Eye Research*, **2012**, 31, 182-94	20.5	65
129	Tumour necrosis factor-mediated macrophage activation in the target organ is critical for clinical manifestation of uveitis. *Clinical and Experimental Immunology*, **2012**, 168, 165-77	6.2	17
128	Gene therapy for noninfectious uveitis. *Ocular Immunology and Inflammation*, **2012**, 20, 394-405	2.8	9
127	Spatially controlling neuronal adhesion on CVD diamond. *Diamond and Related Materials*, **2012**, 23, 100-104	3.5	32
126	A randomized trial of tacrolimus versus tacrolimus and prednisone for the maintenance of disease remission in noninfectious uveitis. *Ophthalmology*, **2012**, 119, 1223-30	7.3	21
125	Persistent inflammation subverts thrombospondin-1-induced regulation of retinal angiogenesis and is driven by CCR2 ligation. *American Journal of Pathology*, **2012**, 180, 235-45	5.8	43
124	Therapeutic dosing of fingolimod (FTY720) prevents cell infiltration, rapidly suppresses ocular inflammation, and maintains the blood-ocular barrier. *American Journal of Pathology*, **2012**, 180, 672-81	5.8	37
123	Shared care approach to managing ophthalmological disease in patients with positive treponemal serology: a case series. *International Journal of STD and AIDS*, **2012**, 23, 291-6	1.4	2
122	Perioperative socialization, care and monitoring of National Institutes of Health miniature swine undergoing ocular surgery and sampling of peripheral blood. *Laboratory Animals*, **2012**, 46, 59-64	2.6	5
121	Current concepts and future directions in the pathogenesis and treatment of non-infectious intraocular inflammation. *Eye*, **2012**, 26, 17-28	4.4	46
120	A model of corneal graft rejection in semi-inbred NIH miniature swine: significant T-cell infiltration of clinically accepted allografts **2012**, 53, 3183-92		12
119	Use of adalimumab in refractory non-infectious childhood chronic uveitis: efficacy in ocular disease--a case cohort interventional study. *Rheumatology*, **2012**, 51, 2199-203	3.9	32
118	Road to fulfilment: taming the immune response to restore vision. *Ophthalmic Research*, **2012**, 48, 43-9	2.9	13

117	Response to Dr Agrawal. *Eye*, **2012**, 26, 890-891	4.4	78
116	Environmental conditioning in the control of macrophage thrombospondin-1 production. *Scientific Reports*, **2012**, 2, 512	4.9	25
115	Signalling of DNA damage and cytokines across cell barriers exposed to nanoparticles depends on barrier thickness. *Nature Nanotechnology*, **2011**, 6, 824-33	28.7	101
114	Lens implant opacification. *Ophthalmology*, **2011**, 118, 2095-6	7.3	1
113	Spatially Controlling Neuronal Adhesion and Inflammatory Reactions on Implantable Diamond. *IEEE Journal on Emerging and Selected Topics in Circuits and Systems*, **2011**, 1, 557-565	5.2	7
112	Punctate inner choroidopathy and multifocal choroiditis with panuveitis share haplotypic associations with IL10 and TNF loci **2011**, 52, 3573-81		32
111	Cancer-associated retinopathy presenting as retinal vasculitis with a negative ERG suggestive of on-bipolar cell pathway dysfunction. *Documenta Ophthalmologica*, **2011**, 123, 59-63	2.2	21
110	Distinguishing between the innate immune response due to ocular inflammation and infection in a child with juvenile systemic granulomatous disease treated with anti-TNF monoclonal antibodies. *Rheumatology*, **2011**, 50, 990-2	3.9	13
109	Plasma exchange and rituximab in the management of acute occlusive retinal vasculopathy secondary to systemic lupus erythematosus. *Ocular Immunology and Inflammation*, **2011**, 19, 379-81	2.8	19
108	Fragile X-related protein FXR1 controls post-transcriptional suppression of lipopolysaccharide-induced tumour necrosis factor-alpha production by transforming growth factor-beta1. *FEBS Journal*, **2010**, 277, 2754-65	5.7	19
107	TNFR1 signalling is a critical checkpoint for developing macrophages that control of T-cell proliferation. *Immunology*, **2010**, 131, 340-9	7.8	13
106	Systemic and local anti-C5 therapy reduces the disease severity in experimental autoimmune uveoretinitis. *Clinical and Experimental Immunology*, **2010**, 159, 303-14	6.2	55
105	Reply to Amissah-Arthur et al. *Eye*, **2010**, 24, 1116-1116	4.4	
104	The effect on visual function of Hydroview intraocular lens opacification: a cross-sectional study. *Eye*, **2010**, 24, 1590-8	4.4	7
103	Patient, surgical, and lens-related factors, and their association with Hydroview intraocular lens opacification. *Eye*, **2010**, 24, 1627-8	4.4	1
102	Dendritic cell physiology and function in the eye. *Immunological Reviews*, **2010**, 234, 282-304	11.3	139
101	Cytokine polymorphism in noninfectious uveitis **2010**, 51, 4133-42		35
100	Plasmapheresis in the management of choroidal vasculitis associated with C-anca positive renal vasculitis. *Retinal Cases and Brief Reports*, **2010**, 4, 356-60	1.1	2

99	Treat early and embrace the evidence in favour of anti-TNF-alpha therapy for Behçet's uveitis. *British Journal of Ophthalmology*, **2010**, 94, 269-70	5.5	18
98	Intravenous immunoglobulin (IVIg) in the management of severe refractory vernal keratoconjunctivitis. *British Journal of Ophthalmology*, **2010**, 94, 667-9	5.5	6
97	In vivo laser-tissue interactions and healing responses from 20- vs 100-millisecond pulse Pascal photocoagulation burns. *JAMA Ophthalmology*, **2010**, 128, 448-55		48
96	Immune mechanisms of intraocular inflammation. *Expert Review of Ophthalmology*, **2010**, 5, 43-58	1.5	5
95	IL-10 regulation of macrophage VEGF production is dependent on macrophage polarisation and hypoxia. *Immunobiology*, **2010**, 215, 796-803	3.4	101
94	Mechanisms of TNF regulation in uveitis: focus on RNA-binding proteins. *Progress in Retinal and Eye Research*, **2010**, 29, 610-21	20.5	54
93	Differential patterning of neuronal, glial and neural progenitor cells on phosphorus-doped and UV irradiated diamond-like carbon. *Biomaterials*, **2010**, 31, 207-15	15.6	34
92	Inflammatory choroidal neovascular membrane in posterior uveitis-pathogenesis and treatment. *Indian Journal of Ophthalmology*, **2010**, 58, 3-10	1.6	52
91	Glucocorticoids and the emerging importance of T cell subsets in steroid refractory diseases. *Immunopharmacology and Immunotoxicology*, **2009**, 31, 1-22	3.2	8
90	Steroid refractory CD4+ T cells in patients with sight-threatening uveitis **2009**, 50, 4273-8		20
89	The use of rituximab in refractory mucous membrane pemphigoid with severe ocular involvement. *British Journal of Ophthalmology*, **2009**, 93, 421-2, 548	5.5	30
88	Clinical review: Anti-TNFalpha therapies in uveitis: perspective on 5 years of clinical experience. *Ocular Immunology and Inflammation*, **2009**, 17, 403-14	2.8	54
87	TNFR1-dependent regulation of myeloid cell function in experimental autoimmune uveoretinitis. *Journal of Immunology*, **2009**, 183, 2321-9	5.3	43
86	CD133+ adult human retinal cells remain undifferentiated in Leukaemia Inhibitory Factor (LIF). *BMC Ophthalmology*, **2009**, 9, 1	2.3	23
85	Diamonds are forever!. *Eye*, **2009**, 23, 1228	4.4	1
84	Influence of microglia on retinal progenitor cell turnover and cell replacement. *Eye*, **2009**, 23, 1939-45	4.4	19
83	Switching biologic agents for uveitis. *Eye*, **2009**, 23, 1868-70	4.4	53
82	Microglia derived IL-6 suppresses neurosphere generation from adult human retinal cell suspensions. *Experimental Eye Research*, **2009**, 89, 757-66	3.7	33

81	Non-infectious pediatric uveitis: an update on immunomodulatory management. *Paediatric Drugs*, **2009**, 11, 229-41	4.2	22
80	Reduced mortality compared with national averages following phacoemulsification cataract surgery: a retrospective observational study. *British Journal of Ophthalmology*, **2009**, 93, 290-5	5.5	10
79	Steroid Sensitivity in Uveitis. *Essentials in Ophthalmology*, **2009**, 45-54	0.2	1
78	The dynamics of leukocyte infiltration in experimental autoimmune uveoretinitis. *Progress in Retinal and Eye Research*, **2008**, 27, 527-35	20.5	77
77	Analysis of retinal cellular infiltrate in experimental autoimmune uveoretinitis reveals multiple regulatory cell populations. *Journal of Autoimmunity*, **2008**, 31, 354-61	15.5	133
76	Mycophenolate mofetil for the treatment of uveitis. *American Journal of Ophthalmology*, **2008**, 146, 752-60, 760.e1-3	4.9	56
75	Cataract surgery with primary intraocular lens implantation in children with chronic uveitis. *JAMA Ophthalmology*, **2008**, 126, 583-4		10
74	The B subunit of Escherichia coli heat-labile enterotoxin inhibits Th1 but not Th17 cell responses in established experimental autoimmune uveoretinitis **2008**, 49, 4008-17		13
73	Fingolimod (FTY720) as an acute rescue therapy for intraocular inflammatory disease. *JAMA Ophthalmology*, **2008**, 126, 1390-5		29
72	The clinical time-course of experimental autoimmune uveoretinitis using topical endoscopic fundal imaging with histologic and cellular infiltrate correlation **2008**, 49, 5458-65		58
71	Lack of IFN-gamma synthesis in aqueous humor during corneal graft rejection correlates with suppressed nitric oxide production by macrophages **2008**, 49, 4923-30		6
70	Protocol for the combined immunosuppression & radiotherapy in thyroid eye disease (CIRTED) trial: a multi-centre, double-masked, factorial randomised controlled trial. *Trials*, **2008**, 9, 6	2.8	19
69	Patterned growth of neuronal cells on modified diamond-like carbon substrates. *Biomaterials*, **2008** , 29, 2573-80	15.6	51
68	Therapeutic Vitrectomy for Noninfectious Uveitis **2008**, 35-45		
67	Practical Manual of Intraocular Inflammation **2008**,		5
66	Cataract surgery in pediatric uveitis. *Journal of Pediatric Ophthalmology and Strabismus*, **2008**, 45, 270-8	0.9	10
65	Nitric Oxide in Experimental Autoimmune Uveoretinitis **2008**, 107-119		
64	TNF Activation and Nitric Oxide Production in EAU **2008**, 121-129		

63	Turnover of resident retinal microglia in the normal adult mouse. *Glia*, **2007**, 55, 1189-98	9	125
62	Ultrastructural evaluation of explanted opacified Hydroview (H60M) intraocular lenses. *British Journal of Ophthalmology*, **2007**, 91, 243-7	5.5	10
61	CD4+CD25(int) T cells in inflammatory diseases refractory to treatment with glucocorticoids. *Journal of Immunology*, **2007**, 179, 7941-8	5.3	32
60	Validity of using vision-related quality of life as a treatment end point in intermediate and posterior uveitis. *British Journal of Ophthalmology*, **2007**, 91, 154-6	5.5	30
59	Use of infliximab in juvenile onset rheumatological disease-associated refractory uveitis: efficacy in joint and ocular disease. *Annals of the Rheumatic Diseases*, **2007**, 66, 840-1	2.4	44
58	The effect of postmortem time, donor age and sex on the generation of neurospheres from adult human retina. *British Journal of Ophthalmology*, **2007**, 91, 1216-8	5.5	20
57	Effects of triamcinolone acetonide injections with and without preservative. *British Journal of Ophthalmology*, **2007**, 91, 1099-101	5.5	3
56	Matrix bound SFD mutant TIMP-3 is more stable than wild type TIMP-3. *British Journal of Ophthalmology*, **2007**, 91, 1073-6	5.5	2
55	Nonsteroidal drugs for the treatment of noninfectious posterior and intermediate uveitis. *Current Opinion in Ophthalmology*, **2007**, 18, 212-9	5.1	22
54	Recovery from macular phototoxicity after corneal triple procedure. *Cornea*, **2007**, 26, 102-4	3.1	10
53	Biologics in the treatment of uveitis. *Current Opinion in Ophthalmology*, **2007**, 18, 481-6	5.1	109
52	Long-term efficacy and tolerance of tacrolimus for the treatment of uveitis. *Ophthalmology*, **2007**, 114, 1000-6	7.3	92
51	Changes in the balance of the tissue inhibitor of matrix metalloproteinases (TIMPs)-1 and -3 may promote keratocyte apoptosis in keratoconus. *Experimental Eye Research*, **2007**, 84, 1125-34	3.7	66
50	Monoclonal antibody-mediated CD200 receptor signaling suppresses macrophage activation and tissue damage in experimental autoimmune uveoretinitis. *American Journal of Pathology*, **2007**, 171, 580-8	5.8	104
49	Tumor Necrosis Factor Alpha-Targeted Therapies in Uveitis **2007**, 177-192		3
48	Online first in the British Journal of Ophthalmology. *British Journal of Ophthalmology*, **2006**, 90, 260-260	5.5	78
47	Mapping immune responses to mRBP-3 1-16 peptide with altered peptide ligands. *Investigative Ophthalmology and Visual Science*, **2006**, 47, 2027-35		5
46	Differences in leukocyte phenotype and interferon-gamma expression in stroma and endothelium during corneal graft rejection. *Experimental Eye Research*, **2006**, 83, 339-47	3.7	16

45	Mechanisms for inducing nasal mucosal tolerance in experimental autoimmune uveoretinitis. *Methods*, **2006**, 38, 69-76	4.6	7
44	Cyclosporine vs tacrolimus therapy for posterior and intermediate uveitis. *JAMA Ophthalmology*, **2005**, 123, 634-41		112
43	Presumed CMV associated necrotizing retinopathy in a non-HIV immunocompromised host. *Clinical and Experimental Ophthalmology*, **2005**, 33, 330-2	2.4	8
42	Enhanced tolerance to autoimmune uveitis in CD200-deficient mice correlates with a pronounced Th2 switch in response to antigen challenge. *Journal of Immunology*, **2005**, 174, 143-54	5.3	29
41	Cytokine gene polymorphism in sympathetic ophthalmia. *Investigative Ophthalmology and Visual Science*, **2005**, 46, 4245-50		43
40	Local administration of an adeno-associated viral vector expressing IL-10 reduces monocyte infiltration and subsequent photoreceptor damage during experimental autoimmune uveitis. *Molecular Therapy*, **2005**, 12, 369-73	11.7	43
39	A selective role for the TNF p55 receptor in autocrine signaling following IFN-gamma stimulation in experimental autoimmune uveoretinitis. *Journal of Immunology*, **2005**, 175, 6286-93	5.3	47
38	Neutralizing tumor necrosis factor activity leads to remission in patients with refractory noninfectious posterior uveitis. *JAMA Ophthalmology*, **2004**, 122, 845-51		55
37	Blocking CD200-CD200 receptor axis augments NOS-2 expression and aggravates experimental autoimmune uveoretinitis in Lewis rats. *Ocular Immunology and Inflammation*, **2004**, 12, 115-25	2.8	41
36	Anti-TNFalpha therapy modulates the phenotype of peripheral blood CD4+ T cells in patients with posterior segment intraocular inflammation. *Investigative Ophthalmology and Visual Science*, **2004**, 45, 170-6		56
35	Murine respiratory tract dendritic cells: isolation, phenotyping and functional studies. *Journal of Immunological Methods*, **2004**, 287, 67-77	2.5	12
34	CD200 maintains microglial potential to migrate in adult human retinal explant model. *Current Eye Research*, **2004**, 28, 427-36	2.9	41
33	Minocycline delays photoreceptor death in the rds mouse through a microglia-independent mechanism. *Experimental Eye Research*, **2004**, 78, 1077-84	3.7	54
32	The role of tumour necrosis factor (TNF-alpha) in experimental autoimmune uveoretinitis (EAU). *Progress in Retinal and Eye Research*, **2004**, 23, 617-37	20.5	145
31	Factors affecting rejection of second corneal transplants in rats. *Transplantation*, **2004**, 77, 492-6	1.8	4
30	Generation of activated sialoadhesin-positive microglia during retinal degeneration. *Investigative Ophthalmology and Visual Science*, **2003**, 44, 2229-34		71
29	Neutralizing tumor necrosis factor-alpha activity suppresses activation of infiltrating macrophages in experimental autoimmune uveoretinitis. *Investigative Ophthalmology and Visual Science*, **2003**, 44, 3034-41		72
28	Predicting endothelial cell loss and long-term corneal graft survival. *Investigative Ophthalmology and Visual Science*, **2003**, 44, 3326-31		201

27	Recent developments in the pharmacological treatment and prevention of corneal graft rejection. *Expert Opinion on Investigational Drugs*, **2003**, 12, 29-37	5.9	19
26	Cytokines and immunopathogenesis of intraocular posterior segment inflammation. *Ocular Immunology and Inflammation*, **2003**, 11, 17-28	2.8	9
25	Control of myeloid activity during retinal inflammation. *Journal of Leukocyte Biology*, **2003**, 74, 161-6	6.5	73
24	Constitutive retinal CD200 expression regulates resident microglia and activation state of inflammatory cells during experimental autoimmune uveoretinitis. *American Journal of Pathology*, **2002**, 161, 1669-77	5.8	175
23	Nitric oxide mediates apoptosis through formation of peroxynitrite and Fas/Fas-ligand interactions in experimental autoimmune uveitis. *American Journal of Pathology*, **2002**, 160, 905-16	5.8	74
22	Retinal microenvironment controls resident and infiltrating macrophage function during uveoretinitis. *Investigative Ophthalmology and Visual Science*, **2002**, 43, 2250-7		72
21	Total dose and frequency of administration critically affect success of nasal mucosal tolerance induction. *British Journal of Ophthalmology*, **2001**, 85, 739-44	5.5	18
20	Single dose intranasal administration of retinal autoantigen generates a rapid accumulation and cell activation in draining lymph node and spleen: implications for tolerance therapy. *British Journal of Ophthalmology*, **2001**, 85, 1001-6	5.5	6
19	Kinetics of leukocyte and myeloid cell traffic in the murine corneal allograft response. *Transplantation*, **2001**, 72, 1292-8	1.8	25
18	Distribution of OX2 antigen and OX2 receptor within retina. *Investigative Ophthalmology and Visual Science*, **2001**, 42, 170-6		54
17	Immune mechanisms of uveitis: insights into disease pathogenesis and treatment. *International Ophthalmology Clinics*, **2000**, 40, 1-18	1.7	41
16	Induction or suppression of a B cell-specific response to self antigen in vivo is dependent upon dendritic cell activation via the TNF-alpha receptor at the time of antigen uptake. *European Journal of Immunology*, **2000**, 30, 2268-80	6.1	4
15	Electric field-directed cell motility involves up-regulated expression and asymmetric redistribution of the epidermal growth factor receptors and is enhanced by fibronectin and laminin. *Molecular Biology of the Cell*, **1999**, 10, 1259-76	3.5	137
14	Mycophenolate mofetil therapy. *Ophthalmology*, **1999**, 106, 1645	7.3	
13	Intranasal administration of retinal antigens induces transient T cell activation and apoptosis within drainage lymph nodes but not spleen. *Journal of Autoimmunity*, **1999**, 12, 145-55	15.5	13
12	Rescue therapy with mycophenolate mofetil in refractory uveitis. *Lancet, The*, **1998**, 352, 35-6	40	121
11	Tacrolimus (FK506) in failed cyclosporin A therapy in endogenous posterior uveitis. *Ocular Immunology and Inflammation*, **1998**, 6, 101-9	2.8	69
10	Neutralizing TNF-alpha activity modulates T-cell phenotype and function in experimental autoimmune uveoretinitis. *Journal of Autoimmunity*, **1998**, 11, 255-64	15.5	88

9	Nasal administration of retinal antigens maintains immunosuppression of uveoretinitis in cyclosporin-A-treated Lewis rats: future treatment of endogenous posterior uveoretinitis?. *Eye*, **1997**, 11 (Pt 4), 445-52	4.4	9
8	Direct ex vivo flow cytometric analysis of human microglial cell CD4 expression: examination of central nervous system biopsy specimens from HIV-seropositive patients and patients with other neurological disease. *Aids*, **1997**, 11, 1699-708	3.5	56
7	What determines the site of inflammation in uveitis and chorioretinitis?. *Eye*, **1997**, 11 (Pt 2), 162-6	4.4	13
6	Phenotypic analysis of retinal leukocyte infiltration during combined cyclosporin A and nasal antigen administration of retinal antigens: delay and inhibition of macrophage and granulocyte infiltration. *Ocular Immunology and Inflammation*, **1997**, 5, 129-40	2.8	11
5	Inhibition of tumor necrosis factor activity minimizes target organ damage in experimental autoimmune uveoretinitis despite quantitatively normal activated T cell traffic to the retina. *European Journal of Immunology*, **1996**, 26, 1018-25	6.1	123
4	Retinal antigen-specific T cells mediate experimental autoimmune uveoretinitis (EAU) in PVG rat a model for tracking antigen-specific CD4(+) T cells in the inflamed eye. *Ocular Immunology and Inflammation*, **1995**, 3, 261-70	2.8	7
3	Retinal antigen specific lymphocytes, TCR-gamma delta T cells and CD5+ B cells cultured from the vitreous in acute sympathetic ophthalmitis. *Autoimmunity*, **1993**, 15, 257-66	3	25
2	The use of lithium clearance studies in the early detection of cyclosporin A (CsA) nephrotoxicity: a protocol of renal function assessment with CsA therapy. *Current Eye Research*, **1992**, 11 Suppl, 215-8	2.9	3
1	UNICORNS: Uveitis in childhood prospective national cohort study protocol. *F1000Research*,9, 1196	3.6	1